Platelet-rich Plasma for Menical Tear

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04040283

Enrollment

Registered

2019-07-31

Start date

2014-01-31

Completion date

2019-11-30

Last updated

2019-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Lesion, Platelet-Rich Plasma

Keywords

Growth factors, Meniscal injury

Brief summary

Meniscal injuries are a common pathology among athletes, and have an impact on the daily or sporting practice of patients. Surgical approach implies sometimes heavy consequences. Platelet-rich-plasma (PRP) has been shown to be effective in accelerating wound healing and tissue regeneration in orthopedic and oral surgery. This clinical trial aims to investigate the safety and efficacy of intraarticular and periferal PRP injection in patients with stable meniscal injury. The pre- and post-interventional clinical outcomes will be compared.

Interventions

PROCEDUREPlatelet-rich plasma (PRP) therapy

Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Skeletally mature patients 18-70 years of age * With diagnosis of meniscus injury * Single tear of the medial and/or lateral meniscus * With no indication of meniscus repair surgery

Exclusion criteria

* Prior history of multiple ligaments injury, associated significant ligament instability: Grade III MCL, Grade III PCL, or ACL deficient knee * Prior history of knee surgery * Discoid meniscus * Osteoarthritic changes (Kellgren Lawrence scale \>2) * Inflammatory diseases (i.e. rheumatoid arthritis) * Underlying bleeding disorder or coagulopathy * Concominant chondral defects (\> 2 ICRS) * Cancer patients * Pregnancy * Patients who will not cooperate with six-month followup

Design outcomes

Primary

Measure	Time frame
Knee injury and Osteoarthritis Outcome Score scale	6months post procedure
Visual Analog Scale	6months post procedure

Secondary

Measure	Time frame
International Knee Documentation Committee - Subjective Knee Evaluation Form	6months post procedure
Satisfaction Level	6months post procedure

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026